1
|
Liu S, Chen X, Zhang L, Lu B. CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells. Cancer Biol Ther 2024; 25:2329372. [PMID: 38494680 PMCID: PMC10950282 DOI: 10.1080/15384047.2024.2329372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 03/07/2024] [Indexed: 03/19/2024] Open
Abstract
Succinylation modification involves in the progression of human cancers. The present study aimed to investigate the role of CPT1A, which is a succinyltransferase in the progression of prostate cancer (PCa). CCK-8 was used to detect the cell viability. Seahorse was performed to evaluate the cell glycolysis. Luciferase assay was used to detect the transcriptional regulation. ChIP was performed to assess the binding between transcriptional factors with the promoters. Co-IP was used to assess the binding between proteins. We found that CPT1A was highly expressed in PCa tissues and cell lines. Silencing of CPT1A inhibited the viability and glycolysis of PCa cells. Mechanistically, CPT1A promoted the succinylation of SP5, which strengthened the binding between SP5 and the promoter of PDPK1. SP5 activated PDPK1 transcription and PDPK1 activated the AKT/mTOR signal pathway. These findings might provide novel targets for the diagnosis or therapy of prostate cancer.
Collapse
Affiliation(s)
- Shufeng Liu
- Medical Department, Xiangyang Integrated Traditional and Western Medicine Hospital, Xiangyang, Hubei, China
| | - Xiaoguang Chen
- Urology Department, Xiangyang Integrated Traditional and Western Medicine Hospital, Xiangyang, Hubei, China
| | - Liqi Zhang
- Laboratory Department, Xiangyang Integrated Traditional and Western Medicine Hospital, Xiangyang, Hubei, China
| | - Bo Lu
- Laboratory Department, Xiangyang Integrated Traditional and Western Medicine Hospital, Xiangyang, Hubei, China
| |
Collapse
|
2
|
Dew A, Lin J, Darmon S, Roswarski J, Shriver C, Zhu K, Chiu A. Survival Among Patients With Multiple Myeloma in the United States Military Health System Compared to the Surveillance, Epidemiology, and End Results (SEER) Program. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2024:S2152-2650(24)00243-X. [PMID: 39034205 DOI: 10.1016/j.clml.2024.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Revised: 06/20/2024] [Accepted: 06/28/2024] [Indexed: 07/23/2024]
Abstract
BACKGROUND Access to health care is an important factor affecting survival of patients with multiple myeloma (MM) in the U.S. general population. The U.S. Military Health System (MHS) provides universal health care to beneficiaries and has been associated with improved survival across multiple malignancies. In this study, we compared survival of MHS beneficiaries with MM with MM patients from the U.S. general population. MATERIALS AND METHODS The Department of Defense's Automated Central Tumor Registry (ACTUR) and the Surveillance, Epidemiology and End Results (SEER) databases were used to extract data for MM patients from MHS and the U.S. general population, respectively. Patients had histologically confirmed MM between 1987 and 2013 and were followed through 2015 for overall survival. Two SEER patients were matched to each ACTUR patient by age group, sex, race, and diagnosis year group. Five and 10-year survival was compared between ACTUR and SEER patients to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI) with adjustment for potential confounders. RESULTS Median survival of the ACTUR patients was 47.1 months (95% CI: 43.9-50.4) compared to 33.0 months (95% CI, 32.0-35.0) of the SEER patients. Five and 10-year death rates were significantly lower for ACTUR patients than the SEER patients with an adjusted HR of 0.74 (95% CI, 0.68-0.81) and 0.79 (95% CI, 0.74-0.85), respectively. The survival advantage of ACTUR patients was preserved when stratified by age, sex, race, and diagnosis year. CONCLUSION MHS beneficiaries with MM had improved overall survival compared to MM patients from the U.S. general population.
Collapse
Affiliation(s)
- Alexander Dew
- Hematology/Oncology Service, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD
| | - Jie Lin
- Department of Surgery, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD; Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Sarah Darmon
- Department of Surgery, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
| | - Joe Roswarski
- Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
| | - Craig Shriver
- Hematology/Oncology Service, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD; Department of Surgery, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Kangmin Zhu
- Department of Surgery, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD; Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD.
| | - Alden Chiu
- Hematology/Oncology Service, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD.
| |
Collapse
|
3
|
Bandi LL, Lin J, Shriver CD, Chesnut GT, Zhu K. Comparative Trends in the Distribution of Prostate Cancer Stage at Diagnosis in the Department of Defense Cancer Registry and the Surveillance, Epidemiology, and End Results Data, 2004-2014. Mil Med 2024:usae269. [PMID: 38836854 DOI: 10.1093/milmed/usae269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 03/13/2024] [Accepted: 05/09/2024] [Indexed: 06/06/2024] Open
Abstract
INTRODUCTION It has been demonstrated that there was an increase in later-stage prostate cancer (PCa) at diagnosis after the U.S. Preventive Services Task Force recommended against prostate-specific antigen screening for prostate cancer. However, the cancer characteristics at diagnosis within the equal-access Military Health System (MHS) during the period have not been described. In this study, we compared PCa stage at diagnosis and its trends between the military health care system and the general public and further compared the trends in tumor stage by race. MATERIALS AND METHODS This study was based on nonidentifiable data from the U.S. Department of Defense's Central Cancer Registry (CCR) and the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. Patients diagnosed between 2004 and 2014 were included. The distributions of PCa stage at diagnosis over time were compared between the 2 populations. Comparisons were further conducted for White and Black patients, respectively. RESULTS Among the 11,895 patients in the CCR and 544,142 patients in SEER, the majority of patients were diagnosed with stage I or II prostate cancer. However, the CCR had a larger proportion of early-stage tumors (stages I and II combined) with 84.3% vs. 80.0% of SEER patients. The proportion of late-stage tumors (stages III and IV combined) increased over time from 2008 for both populations and the proportion of early-stage tumors decreased for the general population. In terms of temporal distributions by race, the trends were the same between White and Black groups in the general population. In the MHS, the trends in the White patients were similar to those in the general population, but in the Black patients, the percentages of stages I and II at diagnosis continued to increase and those of stages III and IV decreased, differing from those in the general population. CONCLUSIONS The MHS consistently diagnosed PCa at an earlier stage than the U.S. general population across all time periods evaluated in this study. Although similar trends were observed for White patients between both populations, the proportion of stages I and II at diagnosis increased from 2012 among Black patients in the MHS, which stands in sharp contrast to trends in the U.S. general population. Although the differences between the two populations may be associated with various factors, differences in accessibility to care and thus the use of prostate-specific antigen testing might play an important role.
Collapse
Affiliation(s)
- Luke L Bandi
- Urology Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - Jie Lin
- Murtha Cancer Center/Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Craig D Shriver
- Murtha Cancer Center/Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - Gregory T Chesnut
- Urology Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - Kangmin Zhu
- Murtha Cancer Center/Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| |
Collapse
|
4
|
Bates AJ, Mitteldorf D, Rosser BRS, Wheldon CW, Polter EJ, Ross MW, Talley KMC, Haggart R, Wright MM, West W, Konety BR. Military service and health-related quality of life among gay and bisexual prostate cancer survivors: Results from the Restore -2 study. BMJ Mil Health 2024:e002649. [PMID: 38548328 DOI: 10.1136/military-2023-002649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Accepted: 02/26/2024] [Indexed: 05/09/2024]
Abstract
INTRODUCTION There are notable disparities in health-related quality of life (HRQOL) between gay and bisexual men (GBM) and heterosexual patients with prostate cancer (PCa); however, the role of past military service is unclear. This study examines HRQOL differences in GBM PCa survivors based on reported military service history. METHODS We used data from the 24-month follow-up survey of the Restore-2 study, a clinical trial which evaluated a rehabilitation programme for GBM PCa survivors. PCa HRQOL was assessed using the Expanded Prostate Cancer Index Composite (EPIC-50) and the Functional Assessment of Cancer Treatment-Prostate (FACT-P). Mental health quality of life was assessed using the Brief Symptom Inventory-18 (BSI-18) scale, while sexual functioning was measured using the Sexual Minorities and Prostate Cancer Scale (SMACS). Multivariable linear regression was used to estimate unadjusted and adjusted mean differences in HRQOL between GBM with and without a reported history of military service. RESULTS In this cross-sectional study of 351 GBM PCa survivors, 47 (13.4%) reported a history of US military service. After adjusting for covariates, participants who reported a history of military service (compared with those with no military service) had clinically better scores on the FACT-P physical, social and emotional well-being domains, as well as higher total FACT-General, EPIC urinary bother and hormonal function scores. Additionally, men with a history of military service reported significantly fewer sexual problems, more sexual confidence and less urinary incontinence in sex. CONCLUSION This exploratory study provides the first evidence that GBM PCa survivors with a military background may have clinically better outcomes than those without military service. Potential reasons may include the structured support and healthcare access associated with military service, fostering resilience and well-being. These findings underscore the need for further research to elucidate how military service influences PCa HRQOL.
Collapse
Affiliation(s)
- Alex J Bates
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - D Mitteldorf
- Malecare Cancer Support, New York, New York, USA
| | - B R S Rosser
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - C W Wheldon
- Department of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, Pennsylvania, USA
| | - E J Polter
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - M W Ross
- Department of Family Medicine and Community Health, Eli Coleman Institute for Sexual and Gender Health, University of Minnesota Medical School, Minneapolis, Minnesota, USA
| | - K M C Talley
- Adult and Gerontological Health, University of Minnesota School of Nursing, Minneapolis, Minnesota, USA
| | - R Haggart
- Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
| | - M M Wright
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
| | - W West
- Department of Writing Studies, University of Minnesota, Minneapolis, Minnesota, USA
| | - B R Konety
- Allina Health Cancer Institute, Allina Health System, Minneapolis, Minnesota, USA
| |
Collapse
|
5
|
Ling J, Gu R, Liu L, Chu R, Wu J, Zhong R, Ye S, Liu J, Fan S. Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer. ACS MATERIALS AU 2024; 4:14-29. [PMID: 38221923 PMCID: PMC10786136 DOI: 10.1021/acsmaterialsau.3c00060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Revised: 09/27/2023] [Accepted: 09/27/2023] [Indexed: 01/16/2024]
Abstract
Radical prostatectomy is a primary treatment option for localized prostate cancer (PCa), although high rates of recurrence are commonly observed postsurgery. Photodynamic therapy (PDT) has demonstrated efficacy in treating nonmetastatic localized PCa with a low incidence of adverse events. However, its limited efficacy remains a concern. To address these issues, various organic polymeric nanoparticles (OPNPs) loaded with photosensitizers (PSs) that target prostate cancer have been developed. However, further optimization of the OPNP design is necessary to maximize the effectiveness of PDT and improve its clinical applicability. This Review provides an overview of the design, preparation, methodology, and oncological aspects of OPNP-based PDT for the treatment of PCa.
Collapse
Affiliation(s)
- Jiacheng Ling
- Department
of Urology, The First Affiliated Hospital
of Anhui Medical University, Institute of Urology & Anhui Province
Key Laboratory of Genitourinary Diseases, Anhui Medical University, 218 Jixi Road, Hefei 230022, China
| | - Rongrong Gu
- College
of Science & School of Plant Protection, Anhui Agricultural University, 130 Changjiang West Road, Hefei 230036, China
| | - Lulu Liu
- School
of Resources and Environment, Anhui Agricultural
University, 130 Changjiang
West Road, Hefei 230036, China
| | - Ruixi Chu
- College
of Science & School of Plant Protection, Anhui Agricultural University, 130 Changjiang West Road, Hefei 230036, China
| | - Junchao Wu
- Department
of Urology, The First Affiliated Hospital
of Anhui Medical University, Institute of Urology & Anhui Province
Key Laboratory of Genitourinary Diseases, Anhui Medical University, 218 Jixi Road, Hefei 230022, China
| | - Rongfang Zhong
- Department
of Urology, The First Affiliated Hospital
of Anhui Medical University, Institute of Urology & Anhui Province
Key Laboratory of Genitourinary Diseases, Anhui Medical University, 218 Jixi Road, Hefei 230022, China
| | - Sheng Ye
- College
of Science & School of Plant Protection, Anhui Agricultural University, 130 Changjiang West Road, Hefei 230036, China
| | - Jian Liu
- Inner
Mongolia University Hohhot, Inner
Mongolia 010021, China
- Dalian
Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, China
- DICP-Surrey
Joint Centre for Future Materials, Department of Chemical and Process
Engineering and Advanced Technology Institute, University of Surrey, Guilford,
Surrey GU27XH, U.K.
| | - Song Fan
- Department
of Urology, The First Affiliated Hospital
of Anhui Medical University, Institute of Urology & Anhui Province
Key Laboratory of Genitourinary Diseases, Anhui Medical University, 218 Jixi Road, Hefei 230022, China
| |
Collapse
|